Stay updated on ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial page.
Latest updates to the ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedLocations information was updated: a new Locations section lists Florida, Minnesota, Ohio, and South Carolina, with the previous state entries removed; the HHS Vulnerability Disclosure link was also removed.SummaryDifference0.5%
- Check26 days agoNo Change Detected
- Check48 days agoChange DetectedPubMed publications description was updated to indicate automatic filling from PubMed, and a revision note shows version v3.3.2.SummaryDifference0.1%
- Check55 days agoChange DetectedThe page no longer displays the government funding lapse notice at the top, and the rest of the study details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check77 days agoChange DetectedThe two screenshots show layout and visual adjustments to the Study Details page; core study information remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%
- Check98 days agoChange DetectedThe page now includes a government-funding and operating-status notice and marks a new version (v3.2.0), replacing the previous v3.1.0.SummaryDifference3%
- Check105 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0. No other content changes detected.SummaryDifference0.1%
Stay in the know with updates to ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial page.